24 / 39
Treatment-Related AEs in ≥ 10%
Nivolumab
N=406
Everolimus
N=397
Any grade
Grade 3
Grade 4
*
Any grade
Grade 3
Grade 4
†
Treatment-related AEs, %
79
18
1
88
33
4
Fatigue
33
2
0
34
3
0
Nausea
14
<1
0
17
1
0
Pruritus
14
0
0
10
0
0
Diarrhea
12
1
0
21
1
0
Decreased appetite
12
<1
0
21
1
0
Rash
10
<1
0
20
1
0
Cough
9
0
0
19
0
0
Anemia
8
2
0
24
8
<1
Dyspnea
7
1
0
13
<1
0
Edema peripheral
4
0
0
14
<1
0
Pneumonitis
4
1
<1
15
3
0
Mucosal inflammation
3
0
0
19
3
0
Dysgeusia
3
0
0
13
0
0
Hyperglycemia
2
1
<1
12
3
<1
Stomatitis
2
0
0
29
4
0
Hypertriglyceridemia
1
0
0
16
4
1
Epistaxis
1
0
0
10
0
0
Based on data cut-off of June 2015.